BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
6/8 — Strong
Priority Review
LEQEMBI (lecanemab) by Eisai is amyloid beta-directed antibody interactions [moa]. Approved for amyloid beta-directed antibody [epc]. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQEMBI (lecanemab) is a monoclonal antibody directed against amyloid beta, administered intravenously to treat early cognitive decline in Alzheimer's disease. It works by binding to amyloid beta protofibrils, reducing amyloid pathology in the brain and slowing cognitive decline in early symptomatic disease stages.
$0.017BPart D
PeakProduct is at peak commercial maturity with modest early Medicare uptake; investment in field force and patient access teams is likely sustained but not in rapid expansion phase.
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
Started Aug 2026
400 enrolled
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
Started Jul 2026
400 enrolled
Alzheimers Disease
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Started Dec 2025
60 enrolled
Alzheimers Disease
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Started Feb 2025
3,000 enrolled
Alzheimer's Disease
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Started Sep 2024
105 enrolled
Alzheimer's Disease
Worked on LEQEMBI at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.